Eli Lilly Israel — Number of class action petitions remained flat by 0.0% to $2.00 in Q4 2025 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
An increase suggests rising legal or regulatory risk in the region, while a decrease indicates a reduction in litigation pressure or improved compliance outcomes.
This metric tracks the total count of active class action lawsuits filed against the company within a specific geographi...
Peers in the pharmaceutical industry typically report litigation counts as part of their legal contingency disclosures, though specific regional counts are often aggregated into global legal risk reporting.
lly_segment_israel_number_of_class_action_petitions| Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|
| Value | $2.00 | $2.00 | $2.00 |
| QoQ Change | — | +0.0% | +0.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.